Johnson Paul M, Gallinger Steven, McLeod Robin S
IBD Research Unit, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Dis Colon Rectum. 2006 Jan;49(1):80-93; discussion 94-5. doi: 10.1007/s10350-005-0228-0.
Surveillance colonoscopy plays an important role in the management of asymptomatic patients known to carry and suspected of carrying hereditary nonpolyposis colorectal cancer gene mutations. Although the shortest interval between surveillance examinations may seem to offer the most benefit to patients, excessive use of this procedure may have unwanted consequences. This study was designed to evaluate the evidence and make recommendations regarding the optimal frequency of surveillance colonoscopy and the age at which to initiate surveillance based on the best available evidence.
MEDLINE was searched for all articles assessing surveillance colonoscopy from 1966 to 2004 by using the MESH terms "hereditary nonpolyposis colorectal cancer" and "screening." The evidence was systematically reviewed and a critical appraisal of the evidence was performed.
There are no randomized, controlled, clinical trials examining the frequency of surveillance colonoscopy in hereditary nonpolyposis colorectal cancer. Three cohort studies were identified for review. There is one cohort study of good quality that provides evidence that surveillance colonoscopy every three years in patients with hereditary nonpolyposis colorectal cancer reduces the risk of developing colorectal cancer and the risk of death. The two remaining cohort studies provide poor evidence on which to make a recommendation.
The best available evidence supports surveillance with complete colonoscopy to the cecum every three years in patients with hereditary nonpolyposis colorectal cancer (B recommendation). There is no evidence to support or refute more frequent screening. Further research is required to examine the potential harms and benefits of more frequent screening. However, given the potential for rapid progression from adenoma to carcinoma and missing lesions at colonoscopy, there is consensus that screening more frequently than every three years is required.
监测结肠镜检查在已知携带或疑似携带遗传性非息肉病性结直肠癌基因突变的无症状患者的管理中起着重要作用。尽管监测检查之间最短的间隔时间似乎对患者最有益,但过度使用该检查可能会产生不良后果。本研究旨在评估相关证据,并根据现有最佳证据就监测结肠镜检查的最佳频率以及开始监测的年龄提出建议。
通过使用医学主题词“遗传性非息肉病性结直肠癌”和“筛查”,检索MEDLINE中1966年至2004年所有评估监测结肠镜检查的文章。对证据进行系统回顾并进行批判性评价。
尚无随机对照临床试验研究遗传性非息肉病性结直肠癌监测结肠镜检查的频率。确定了三项队列研究进行综述。有一项质量良好的队列研究提供了证据,表明遗传性非息肉病性结直肠癌患者每三年进行一次监测结肠镜检查可降低患结直肠癌的风险和死亡风险。其余两项队列研究提供的证据不足以做出推荐。
现有最佳证据支持遗传性非息肉病性结直肠癌患者每三年进行一次全结肠镜检查至盲肠的监测(B级推荐)。没有证据支持或反驳更频繁的筛查。需要进一步研究以检验更频繁筛查的潜在危害和益处。然而,鉴于腺瘤可能迅速进展为癌以及结肠镜检查时可能遗漏病变,人们一致认为需要每三年进行一次以上的筛查。